Board approves Q2 results with unmodified review; NCLT clears Genxrx acquisition
Board met on 17 October 2026 and approved unaudited standalone results for the quarter and half year ended 30 September 2026.
By ScoutQuest · · 2 min read
| Line item | Latest | Year ago | YoY | Prev qtr | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 17,590.16 | 14,791.49 | +18.9% | 16,563.17 | +6.2% |
| Total income | 17,679.40 | 14,956.78 | +18.2% | 16,644.31 | +6.2% |
| Profit before tax | 1,847.59 | 1,596.21 | +15.7% | 1,645.83 | +12.3% |
| Profit after tax | 1,409.40 | 1,110.92 | +26.9% | 1,369.80 | +2.9% |
| Total comprehensive income | 1,431.85 | 1,129.62 | +26.8% | 1,392.25 | +2.8% |
| Basic EPS | 4.19 | 3.53 | +18.7% | 4.07 | +2.9% |
- Profit after tax YoY growth
- +26.9%
- Period
- Quarter Ended 30 Sept 2026 (Unaudited)
Auditor's review
Conclusion: Unmodified
Notes to the results
- Discontinued operations (Tarapur units, Dahej land) shown separately; loss after tax from discontinued operations Rs. (28.58) lakhs for the quarter ended 30 Sept 2026.
- A portion of Dahej plot D-2/CH/42 & D-2/CH/43 was sold in the quarter; sale completed subsequent to 30 September 2026.
- Unit at Plot No. N-178, MIDC Tarapur approved for sale on 23 June 2026 (expected by 31 October 2026); classified as Property Held for Sale.
- Genrx Pharmaceuticals acquired for Rs.1,085.00 lakhs not consolidated; NCLT approved acquisition on 13 October 2026, to become wholly owned subsidiary.
What the board approved
Bajaj Healthcare's board met on 17 October 2026 and approved the unaudited standalone financial results for the quarter and half year ended 30 September 2026, together with the limited review report of Walker Chandhiok & Co LLP. The numbers are standalone. The company deals in pharmaceutical products (formulations and active pharmaceutical ingredients) and reports a single segment, Pharmaceuticals.
Auditor's review conclusion
The auditors reviewed the statement under SRE 2410 and stated that nothing came to their attention that causes them to believe the statement has not disclosed the information required, or that it contains any material misstatement. That is an unmodified review conclusion. A review is narrower in scope than an audit and does not express an audit opinion.
Quarter ended 30 September 2026 (standalone, Rs. in lakhs)
- Revenue from operations: Rs. 17,590.16 lakhs, against Rs. 14,791.49 lakhs in the same quarter a year earlier
- Profit for the period: Rs. 1,409.40 lakhs, against Rs. 1,110.92 lakhs a year earlier
Half year ended 30 September 2026 (standalone)
- Revenue from operations: Rs. 34,153.33 lakhs
- Profit for the period: Rs. 2,779.20 lakhs
Preferential issue proceeds
The company had allotted equity shares and convertible warrants on a preferential basis, raising Rs. 20,497.00 lakhs in aggregate. The proceeds are earmarked for repayment of loan, investment in capital expenditure and general corporate purposes, and a part of the money remained unutilised as at 30 September 2026.
Genxrx acquisition
- In April 2025 the company agreed to acquire Genxrx Pharmaceuticals Private Limited (In Liquidation) on a going concern basis for a total consideration of Rs. 1,085.00 lakhs.
- The National Company Law Tribunal, Mumbai Bench, passed an order on 13 October 2026 approving the acquisition on a going concern basis.
- Genxrx will become a wholly owned subsidiary of Bajaj Healthcare, subject to implementation of the terms of the order and completion of applicable procedural and legal formalities.
Assets held for sale
- The board had approved the sale/disposal, on a going concern basis, of units at MIDC Tarapur and vacant industrial land at Dahej Industrial Area, GIDC, Bharuch; these are classified as held for sale and their results are shown as discontinued operations.
- One unit at plot No. N-92 was sold during the quarter ended 31 March 2026 and the Dahej plot was sold during the current quarter.
- Sale of the unit at plot No. N-178, MIDC Tarapur was approved by the board on 23 June 2026, with an expected conclusion by 31 October 2026.
What a retail investor can take away
The update combines the quarterly numbers with two structural developments — an NCLT-approved going-concern acquisition that will add a wholly owned subsidiary, and the ongoing sale of identified units and land parcels whose results are reported separately as discontinued operations. The auditor's unmodified review conclusion and the year-on-year movement in revenue from operations and profit for the period are the main quantitative markers in the statement.
Also from Bajaj Healthcare
Bajaj Healthcare uploads audio recording of Q2 & H1 FY27 earnings call held October 19, 2026
19 Oct 2026
Q2 FY27 release: revenue up 18.9% YoY to Rs. 175.9 Crore, PAT up 26.9%, credit rating upgraded
17 Oct 2026
Monitoring agency report: nil deviation in use of Rs. 204.97 crore preferential issue proceeds
17 Oct 2026
More numbers
- Revenue from operations, half year ended 30 Sept 2026 (standalone, Rs. in lakhs)34,153.33
- Profit for the period, half year ended 30 Sept 2026 (standalone, Rs. in lakhs)2,779.20
- Aggregate amount raised via preferential issue of shares and warrants (Rs. in lakhs)20,497.00
- Total consideration for Genxrx Pharmaceuticals acquisition (Rs. in lakhs)1,085.00
- Total income, latest quarter17,679.40 (Rs. In Lakhs)
- Total income, year-ago quarter14,956.78 (Rs. In Lakhs)
- Total income, previous quarter16,644.31 (Rs. In Lakhs)
- Total comprehensive income, latest quarter1,431.85 (Rs. In Lakhs)
- Total comprehensive income, year-ago quarter1,129.62 (Rs. In Lakhs)
- Total comprehensive income, previous quarter1,392.25 (Rs. In Lakhs)
- Profit after tax, latest quarter1,409.40 (Rs. In Lakhs)
- Profit after tax, year-ago quarter1,110.92 (Rs. In Lakhs)
- Profit after tax, previous quarter1,369.80 (Rs. In Lakhs)
- Revenue from operations, latest quarter17,590.16 (Rs. In Lakhs)
- Revenue from operations, year-ago quarter14,791.49 (Rs. In Lakhs)
- Revenue from operations, previous quarter16,563.17 (Rs. In Lakhs)
- Profit before tax, latest quarter1,847.59 (Rs. In Lakhs)
- Profit before tax, year-ago quarter1,596.21 (Rs. In Lakhs)
- Profit before tax, previous quarter1,645.83 (Rs. In Lakhs)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.